Phase II study of a biweekly regimen of vinorelbine and cisplatin in advanced non-small cell lung cancer

Chih Hung Chen, Chih Ming Lin, Kuo Chin Kao, John W.C. Chang, Thomas Chang Yao Tsao

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Many novel agents, including vinorelbine, gemcitabine, paclitaxel and docetaxel, have been administrated in combination with cisplatin to patients with advanced non-small cell lung cancer (NSCLC). Of these drugs, vinorelbine is reported to have a high response rate and acceptable toxicity level. In an attempt to increase treatment activity, a biweekly regimen using vinorelbine and cisplatin was designed. Methods: From March 2001 to July 2003, 43 patients with NSCLC, who met the selection criteria, were enrolled. Of the 43 patients, 28 were male and 15 were female. All of them had their diagnosis confirmed histologically and were in an advanced stage, i.e., stage IIIB with pleural effusion or stage IV. Vinorelbine 30 or 35 mg/m2 and cisplatin 50 mg/m2 were given intravenously every 2 weeks. Results: Of the 43 assessable patients, 11 achieved a Partial Response (PR) and 13 had a Stable Disease (SD). Overall response was 25.6% (95% CI 12.0%-39.2%). Median survival was 9.0 months (95% CI: 6.2-11.8) and the 1-year survival rate was 32.6%. Median time to disease progression was 3.9 months (95% CI 2.4-5.4 months). The major hematological toxicity was neutropenia. Seven patients (16.3%) developed grade 3 neutropenia and 17 patients (39.5%) developed grade 4 neutropenia. Eight patients developed febrile neutropenia, 4 patients had confirmed sepsis, 2 of which died due to sepsis. One patient had grade 3 thrombocytopenia. Six patients (7%) developed severe anemia. Ten patients (23.3%) had grade 3/4 nausea and vomiting. Only 2 patients developed grade 3 neuropathy. Conclusions: This biweekly regimen of vinorelbine and cisplatin is effective against advanced NSCLC. Due to the high incidence of neutropenia, this regimen did not improve therapeutic efficacy and its dose intensity is less than that of a conventional schedule.

Original languageEnglish
Pages (from-to)249-255
Number of pages7
JournalChang Gung Medical Journal
Volume30
Issue number3
Publication statusPublished - May 1 2007
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Cisplatin
Neutropenia
docetaxel
gemcitabine
vinorelbine
Sepsis
Febrile Neutropenia
Pleural Effusion
Paclitaxel
Nausea
Patient Selection
Vomiting
Disease Progression
Anemia
Appointments and Schedules
Survival Rate
Survival

Keywords

  • Chemotherapy
  • Cisplatin
  • Non-small cell lung cancer
  • Vinorelbine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Phase II study of a biweekly regimen of vinorelbine and cisplatin in advanced non-small cell lung cancer. / Chen, Chih Hung; Lin, Chih Ming; Kao, Kuo Chin; Chang, John W.C.; Tsao, Thomas Chang Yao.

In: Chang Gung Medical Journal, Vol. 30, No. 3, 01.05.2007, p. 249-255.

Research output: Contribution to journalArticle

Chen, Chih Hung ; Lin, Chih Ming ; Kao, Kuo Chin ; Chang, John W.C. ; Tsao, Thomas Chang Yao. / Phase II study of a biweekly regimen of vinorelbine and cisplatin in advanced non-small cell lung cancer. In: Chang Gung Medical Journal. 2007 ; Vol. 30, No. 3. pp. 249-255.
@article{0d2ecab83ee34bd68f489cf8d6e8987a,
title = "Phase II study of a biweekly regimen of vinorelbine and cisplatin in advanced non-small cell lung cancer",
abstract = "Background: Many novel agents, including vinorelbine, gemcitabine, paclitaxel and docetaxel, have been administrated in combination with cisplatin to patients with advanced non-small cell lung cancer (NSCLC). Of these drugs, vinorelbine is reported to have a high response rate and acceptable toxicity level. In an attempt to increase treatment activity, a biweekly regimen using vinorelbine and cisplatin was designed. Methods: From March 2001 to July 2003, 43 patients with NSCLC, who met the selection criteria, were enrolled. Of the 43 patients, 28 were male and 15 were female. All of them had their diagnosis confirmed histologically and were in an advanced stage, i.e., stage IIIB with pleural effusion or stage IV. Vinorelbine 30 or 35 mg/m2 and cisplatin 50 mg/m2 were given intravenously every 2 weeks. Results: Of the 43 assessable patients, 11 achieved a Partial Response (PR) and 13 had a Stable Disease (SD). Overall response was 25.6{\%} (95{\%} CI 12.0{\%}-39.2{\%}). Median survival was 9.0 months (95{\%} CI: 6.2-11.8) and the 1-year survival rate was 32.6{\%}. Median time to disease progression was 3.9 months (95{\%} CI 2.4-5.4 months). The major hematological toxicity was neutropenia. Seven patients (16.3{\%}) developed grade 3 neutropenia and 17 patients (39.5{\%}) developed grade 4 neutropenia. Eight patients developed febrile neutropenia, 4 patients had confirmed sepsis, 2 of which died due to sepsis. One patient had grade 3 thrombocytopenia. Six patients (7{\%}) developed severe anemia. Ten patients (23.3{\%}) had grade 3/4 nausea and vomiting. Only 2 patients developed grade 3 neuropathy. Conclusions: This biweekly regimen of vinorelbine and cisplatin is effective against advanced NSCLC. Due to the high incidence of neutropenia, this regimen did not improve therapeutic efficacy and its dose intensity is less than that of a conventional schedule.",
keywords = "Chemotherapy, Cisplatin, Non-small cell lung cancer, Vinorelbine",
author = "Chen, {Chih Hung} and Lin, {Chih Ming} and Kao, {Kuo Chin} and Chang, {John W.C.} and Tsao, {Thomas Chang Yao}",
year = "2007",
month = "5",
day = "1",
language = "English",
volume = "30",
pages = "249--255",
journal = "Chang Gung Medical Journal",
issn = "0255-8270",
publisher = "Chang Gung Medical Journal",
number = "3",

}

TY - JOUR

T1 - Phase II study of a biweekly regimen of vinorelbine and cisplatin in advanced non-small cell lung cancer

AU - Chen, Chih Hung

AU - Lin, Chih Ming

AU - Kao, Kuo Chin

AU - Chang, John W.C.

AU - Tsao, Thomas Chang Yao

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Background: Many novel agents, including vinorelbine, gemcitabine, paclitaxel and docetaxel, have been administrated in combination with cisplatin to patients with advanced non-small cell lung cancer (NSCLC). Of these drugs, vinorelbine is reported to have a high response rate and acceptable toxicity level. In an attempt to increase treatment activity, a biweekly regimen using vinorelbine and cisplatin was designed. Methods: From March 2001 to July 2003, 43 patients with NSCLC, who met the selection criteria, were enrolled. Of the 43 patients, 28 were male and 15 were female. All of them had their diagnosis confirmed histologically and were in an advanced stage, i.e., stage IIIB with pleural effusion or stage IV. Vinorelbine 30 or 35 mg/m2 and cisplatin 50 mg/m2 were given intravenously every 2 weeks. Results: Of the 43 assessable patients, 11 achieved a Partial Response (PR) and 13 had a Stable Disease (SD). Overall response was 25.6% (95% CI 12.0%-39.2%). Median survival was 9.0 months (95% CI: 6.2-11.8) and the 1-year survival rate was 32.6%. Median time to disease progression was 3.9 months (95% CI 2.4-5.4 months). The major hematological toxicity was neutropenia. Seven patients (16.3%) developed grade 3 neutropenia and 17 patients (39.5%) developed grade 4 neutropenia. Eight patients developed febrile neutropenia, 4 patients had confirmed sepsis, 2 of which died due to sepsis. One patient had grade 3 thrombocytopenia. Six patients (7%) developed severe anemia. Ten patients (23.3%) had grade 3/4 nausea and vomiting. Only 2 patients developed grade 3 neuropathy. Conclusions: This biweekly regimen of vinorelbine and cisplatin is effective against advanced NSCLC. Due to the high incidence of neutropenia, this regimen did not improve therapeutic efficacy and its dose intensity is less than that of a conventional schedule.

AB - Background: Many novel agents, including vinorelbine, gemcitabine, paclitaxel and docetaxel, have been administrated in combination with cisplatin to patients with advanced non-small cell lung cancer (NSCLC). Of these drugs, vinorelbine is reported to have a high response rate and acceptable toxicity level. In an attempt to increase treatment activity, a biweekly regimen using vinorelbine and cisplatin was designed. Methods: From March 2001 to July 2003, 43 patients with NSCLC, who met the selection criteria, were enrolled. Of the 43 patients, 28 were male and 15 were female. All of them had their diagnosis confirmed histologically and were in an advanced stage, i.e., stage IIIB with pleural effusion or stage IV. Vinorelbine 30 or 35 mg/m2 and cisplatin 50 mg/m2 were given intravenously every 2 weeks. Results: Of the 43 assessable patients, 11 achieved a Partial Response (PR) and 13 had a Stable Disease (SD). Overall response was 25.6% (95% CI 12.0%-39.2%). Median survival was 9.0 months (95% CI: 6.2-11.8) and the 1-year survival rate was 32.6%. Median time to disease progression was 3.9 months (95% CI 2.4-5.4 months). The major hematological toxicity was neutropenia. Seven patients (16.3%) developed grade 3 neutropenia and 17 patients (39.5%) developed grade 4 neutropenia. Eight patients developed febrile neutropenia, 4 patients had confirmed sepsis, 2 of which died due to sepsis. One patient had grade 3 thrombocytopenia. Six patients (7%) developed severe anemia. Ten patients (23.3%) had grade 3/4 nausea and vomiting. Only 2 patients developed grade 3 neuropathy. Conclusions: This biweekly regimen of vinorelbine and cisplatin is effective against advanced NSCLC. Due to the high incidence of neutropenia, this regimen did not improve therapeutic efficacy and its dose intensity is less than that of a conventional schedule.

KW - Chemotherapy

KW - Cisplatin

KW - Non-small cell lung cancer

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=34547756808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547756808&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 249

EP - 255

JO - Chang Gung Medical Journal

JF - Chang Gung Medical Journal

SN - 0255-8270

IS - 3

ER -